Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT06599021
Recruiting Not applicable

Swallowing Difficulties in People Over 60 Years: Prevalence, Degree of Difficulty and Intervention

NCT06599021 · tracked via the Priya Life Science Sweden tracker
Sponsor
Lisa Tuomi
Phase
Not applicable
Started
2024-12-01
Last updated
2026-04-27

Condition(s) studied

DysphagiaInterventionAgeing

Investigational drug(s) / intervention(s)

Muscular strengthening trainingSkill-based training

Muscular strengthening training: 6 weeks daily muscular strengthening training.

Skill-based training: 15 sessions skill based swallowing training lead by a speech and language pathologist during 3 weeks.

Study summary

Participants included in SCAPIS2 (Swedish Cardio Pulmonary bioimage study) are screened regarding swallowing difficulty using a timed water swallow test. Participants who show signs of swallowing difficulty (dysphagia) are included in the present study, which encompasses s flexible endoscopic evaluation of swallowing function (FEES). Participants showing a moderate-severe dysphagia are randomized into one of three intervention groups: muscle strengthening training, skill-based swallowing training and a control group who will receive compensatory treatment. The study is expected to improve diagnostics and treatment of swallowing difficulties in an ageing population.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Participation in SCAPIS2 * Swallowing dysfunction according to timed water swallow test or * Swallowing dysfunction according to self-report Exclusion Criteria: * Severely impaired intellectual abilities. * Inability to consent to inclusion in the study. * Inability to answer written questionnaires in Swedish Inclusion of non-dysphagia control cohort: No signs of aspiration, slow swallowing (\<10 ml/sec) or self-rated difficulties with eating and swallowing in sub-study SCAPIS2

Primary outcome measure(s)

  • Penetration-aspiration score (PAS) — Baseline to post-intervention (6 weeks)
    Ranges from 1-8 where 8 indicates worst possible aspiration score. Swallowing safety measured from Flexible Endoscopic Examination of Swallowing (FEES).

Trial sites (1)

FacilityCityRegionStatus
Sahlgrenska University Hospital Gothenburg Sweden Recruiting

Other trials for the same condition

Dysphagia Evaluation After Stroke- Effect Oral Neuromuscular Training on Swallowing Dysfunction Recruiting
Dysphagia After Anterior Cervical Spine Surgery Recruiting
Bring Sleep to Life - Evaluation and Description of a Sleep Intervention in Emergency Care Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06599021 on ClinicalTrials.gov ↗ ← All trials in Sweden